期刊
GUT
卷 71, 期 3, 页码 497-508出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2020-322935
关键词
-
资金
- INSERM
- Universite de Paris
- ANR [Nr18-CE14-0005]
- Foundation ARC-Recherche Clinique [PGA1 RF20180206809]
- Foundation Princesse Grace
- Association Francaise Des Intolerants au Gluten (AFDIAG)
- Investissement d'Avenir grant [ANR-10-IAHU-01]
- ANR
- ARC
The study identified mutations activating the JAK1-STAT3 pathway as the main drivers of enteropathy-associated T-cell lymphoma, potentially in combination with mutations in negative regulators of NF-kappa B. These mutations could promote the clonal emergence of malignant lymphocytes in the cytokine-rich coeliac intestine, and are attractive therapeutic targets for treating refractory celiac disease and blocking progression towards EATL.
Objective Enteropathy-associated T-cell lymphoma (EATL) is a rare but severe complication of coeliac disease (CeD), often preceded by low-grade clonal intraepithelial lymphoproliferation, referred to as type II refractory CeD (RCDII). Knowledge on underlying oncogenic mechanisms remains scarce. Here, we analysed and compared the mutational landscape of RCDII and EATL in order to identify genetic drivers of CeD-associated lymphomagenesis. Design Pure populations of RCDII-cells derived from intestinal biopsies (n=9) or sorted from blood (n=2) were analysed by whole exome sequencing, comparative genomic hybridisation and RNA sequencing. Biopsies from RCDII (n=50), EATL (n=19), type I refractory CeD (n=7) and uncomplicated CeD (n=18) were analysed by targeted next-generation sequencing. Moreover, functional in vitro studies and drug testing were performed in RCDII-derived cell lines. Results 80% of RCDII and 90% of EATL displayed somatic gain-of-functions mutations in the JAK1-STAT3 pathway, including a remarkable p.G1097 hotspot mutation in the JAK1 kinase domain in approximately 50% of cases. Other recurrent somatic events were deleterious mutations in nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kappa B) regulators TNFAIP3 and TNIP3 and potentially oncogenic mutations in TET2, KMT2D and DDX3X. JAK1 inhibitors, and the proteasome inhibitor bortezomib could block survival and proliferation of malignant RCDII-cell lines. Conclusion Mutations activating the JAK1-STAT3 pathway appear to be the main drivers of CeD-associated lymphomagenesis. In concert with mutations in negative regulators of NF-kappa B, they may favour the clonal emergence of malignant lymphocytes in the cytokine-rich coeliac intestine. The identified mutations are attractive therapeutic targets to treat RCDII and block progression towards EATL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据